Conjunctiva

Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023
Surgery, Medical Devices, Health, Pharmaceutical, Optical, Tradition, Intraocular lens, Aperture, ASCRS, Astigmatism, Pain, Employment, Telecanthus, Incidence, Patient, Outcome, Viral, Steroid, Herpes simplex, NYSE, Chickenpox, Very-small-aperture terminal, Conjunctiva, Cornea, Comparative Effectiveness Research Translation Network, SM, Optic nerve, Cataract, FDA, Emerging technologies, Fungal infection, Refractive surgery, Use, Sclera, Eye, Bausch, History, Thought, American Society of Cataract and Refractive Surgery, Slit lamp, ARMOR, Glaucoma, DED, IOP, Contact lens, Infection, OVD, Inflammation, Vaccinia, Bausch & Lomb, Range, Convention (norm), Visual acuity, Society, Pharmaceutical industry, Telescopic sight, Telescope, Wood drying, Dentistry, Hospital, Retail, Veterinary medicine, Fused quartz, Vaccine, Dietary supplement, Emmetropia, Refraction, IOL

The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.

Key Points: 
  • The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.
  • Others include a retrospective chart review on the use of LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% in refractive surgery and numerous presentations focused on Bausch + Lomb surgical IOL pipeline programs.
  • New data from the Bausch + Lomb Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study will also be presented.
  • “Clinical Evaluation of the Outcomes of Two Preloaded Monofocal IOLs Implanted Bilaterally in Cataract Patients.” Shultz et al.

Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

Retrieved on: 
Thursday, April 20, 2023
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Hypersensitivity, Meibomian gland, Fetus, Safety, Cataract, Fungus, Dose, Development, Floater, Data analysis, Photophobia, Patient, Risk, Macular edema, Association for Research in Vision and Ophthalmology, Virus, NYSE, Chickenpox, Canker, ARVO, Pregnancy, Conjunctiva, Photopsia, Viral, HPA, Chemosis, Intraocular pressure, Administration, Uveitis, Bacteria, Chalazion, Hypothalamic–pituitary hormone, FDA, Lomb, Hyperglycemia, Perception, Efficacy, Eye, History, Sanfilippo, ARMOR, Triamcinolone, Cover My Eyes (Pain and Heaven), Intraocular lens, Glaucoma, Cornea, Research and development, Nursing, Telecanthus, Vaccinia, Asbell, Bausch & Lomb, Meibomian gland dysfunction, Visual acuity, Pharmaceutical industry, Wood drying, Vaccine, Telescopic sight, Dietary supplement, Ophthalmology, Kalahari Desert

“Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.

Key Points: 
  • “Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.
  • “Early Adoption of Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey.” Chang et al.
  • “Longitudinal Analysis of In Vitro Antibiotic Resistance Among Ocular Staphylococci Collected in the ARMOR study.” Asbell et al.
  • To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .

Santgar Announces the Launch of Its Newest Medicine, "Excentera LS," Which Will Treat Immune-Mediated Disorders That Cause Dry Eyes in Dogs

Retrieved on: 
Tuesday, February 7, 2023
KCS, Cornea, Inflammation, Veterinarian, Conjunctiva, DVM, Dog, Duane syndrome, PTF, PETS, Eye, Animal, Disease, Research, Veterinary medicine, Pharmaceutical industry

Excentera LS is an innovative therapeutic option for veterinarians and pet owners to treat eye diseases.

Key Points: 
  • Excentera LS is an innovative therapeutic option for veterinarians and pet owners to treat eye diseases.
  • It is a once-per-month, easy-to-administer solution that can help restore eye comfort and vision to dogs and other pets suffering from dry eye.
  • Santgar also has an entire education division dedicated to teaching veterinarians how to use and administer their products most effectively.
  • Santgar's major differentiator in providing innovative medical solutions is its ability to produce and share knowledge to grow with its clients.

Santgar Has Officially Announced its Newest Product, "Excentera LS," Which Will Treat Immune-Mediated Diseases in Dogs That Cause Dry Eye

Retrieved on: 
Saturday, February 4, 2023
Disease, Health, Veterinarian, Dog, Duane syndrome, KCS, Quality of life, Animal, Conjunctiva, PETS, PTF, Cornea, Knowledge, Research, Eye, Inflammation, Pharmaceutical industry, Veterinary medicine

"We are proud to be launching Excentera LS, an innovative medication that promises to help improve the quality of life of dogs suffering from dry eye," says Diego García Santisteban, CEO of Santgar.

Key Points: 
  • "We are proud to be launching Excentera LS, an innovative medication that promises to help improve the quality of life of dogs suffering from dry eye," says Diego García Santisteban, CEO of Santgar.
  • KCS is a common disease that causes dry eye in dogs.
  • Excentera LS is an innovative therapeutic option for veterinarians and pet owners to treat eye diseases.
  • It is a once-per-month, easy-to-administer solution that can help restore eye comfort and vision to dogs and other pets suffering from dry eye.

Global Dry Eye Syndrome Treatment Market Report 2022 to 2028: Featuring AbbVie, Novartis, Sun Pharmaceuticals Industries and OASIS Medical Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023
Pharmaceutical, Health, Optical, Plasma protein binding, Approved drug, DE, Therapy, Tears, Duane syndrome, Cornea, FDA, Eyelid, Irritation, Conjunctiva, Growth, Patient, Bausch & Lomb, Loteprednol, Dry eye syndrome, Clinical trial, DED, Eye, Market share, Investment, Mucus, Printed circuit board, Cosmetics, Hospital, Pharmaceutical industry, Dose

The Global Dry Eye Syndrome Treatment Market size is expected to reach $6.5 billion by 2028, rising at a market growth of 4.5% CAGR during the forecast period.

Key Points: 
  • The Global Dry Eye Syndrome Treatment Market size is expected to reach $6.5 billion by 2028, rising at a market growth of 4.5% CAGR during the forecast period.
  • As these development continue to proceed, they aid in the expansion of the dry eye syndrome treatment market.
  • This demonstrates significant drug approval costs that are expected to have an impact on the market for dry eye medications.
  • Additionally, long waiting times also add up to lost money for these manufacturers, and as such hampers the growth of the dry eye syndrome treatment market.

The Worldwide Allergic Conjunctivitis Industry is Estimated to Reach $2.9 Billion by 2031 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 4, 2023
Health, Optical, Conjunctivitis, Allergic conjunctivitis, Allergy, Conjunctiva, Allergen, Market share, Common, Allergic rhinitis, Eyelid, Urbanization, Porter's five forces analysis, Pollen, Itchy, Gonorrhea, National Centre for Cold-chain Development, Semen, Growth, Patient, Benchmarking, Vertically transmitted infection, Asthma, Distribution, Spore, Eye, STI, Asthma and Allergy Foundation of America, Prevalence, Chlamydia, Cosmetics, Marketing

The global allergic conjunctivitis market was valued at $1,937.99 million in 2021, and is estimated to reach $2,954.2 million by 2031, growing at a CAGR of 4.28% from 2022 to 2031.

Key Points: 
  • The global allergic conjunctivitis market was valued at $1,937.99 million in 2021, and is estimated to reach $2,954.2 million by 2031, growing at a CAGR of 4.28% from 2022 to 2031.
  • An allergic reaction to things such as pollen, mold, or spores can result in an eye inflammation known as allergic conjunctivitis.
  • The major factors that drive the growth of the allergic conjunctivitis market are increase in patient population suffering from ocular allergies.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the allergic conjunctivitis market analysis from 2021 to 2031 to identify the prevailing allergic conjunctivitis market opportunities.

CorNeat Vision Unveils the EverMatrix™: A Novel Nondegradable Synthetic Material That Permanently Integrates with Live Human Tissue

Retrieved on: 
Wednesday, October 26, 2022
Disease, Matrix, Polymer, Life, Medicine, VP, Granuloma, Standard of care, Capillary, Skeleton, Entrepreneurship, Technology, ECM, Immune system, Health, Cornea, CEO, Conjunctiva, Skin, CMO, Gums, FDA, Solution, Human, Silk

RA'ANANA, Israel, Oct. 26, 2022 /PRNewswire/ -- CorNeat Vision, an Israeli biomimetic implant and technology company, unveiled the EverMatrix™, a revolutionary tissue-integrating material technology. The EverMatrix™ is the world's first nondegradable, 100% synthetic, biomimetic Extra Cellular Matrix (ECM) - the skeleton of the tissue, that seamlessly integrates with live human tissue for life. Once implanted, it triggers complex biological processes stimulating cellular (fibroblast) proliferation and colonization that leads to full tissue integration without triggering an adverse foreign body response.

Key Points: 
  • RA'ANANA, Israel, Oct. 26, 2022 /PRNewswire/ -- CorNeat Vision, an Israeli biomimetic implant and technology company, unveiled the EverMatrix, a revolutionary tissue-integrating material technology.
  • The EverMatrix is the world's first nondegradable, 100% synthetic, biomimetic Extra Cellular Matrix (ECM) - the skeleton of the tissue, that seamlessly integrates with live human tissue for life.
  • The EverMatrix was originally developed as part of CorNeat Vision's artificial cornea project, where there was a need to permanently and bio-mechanically integrate an artificial lens made from polymers, with resident ocular tissue.
  • Until now, no one has found a way to seamlessly and permanently integrate synthetic material and literally embed it with surrounding tissue.

Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting

Retrieved on: 
Wednesday, July 6, 2022
Suprachoroidal drug delivery, Canadian Securities Administrators, Patient, SCS, Canker, COVID-19, Hypersensitivity, Bausch & Lomb, Bacteria, Lens (anatomy), Floater, Uveitis, Degenerative disease, Pregnancy, Fetus, FDA, Dose, Triamcinolone, ASRS, Conjunctiva, Cataract, Nursing, Hypothalamic–pituitary hormone, Macular edema, NYSE, Cushing's syndrome, Cornea, Instagram, Twitter, Eye, LinkedIn, Administration, Duane syndrome, HPA, Virus, Chickenpox, News, Chalazion, Chemosis, U.S. Securities and Exchange Commission, History, Photophobia, Meibomian gland, Glaucoma, Fungus, Risk, Vaccinia, Cover My Eyes (Pain and Heaven), Visual acuity, Intraocular pressure, Facebook, Fear, Society, Photopsia, Hyperglycemia, Pharmaceutical industry, Silviculture, Vaccine, Telescopic sight

VAUGHAN, ON, July 6, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that five presentations highlighting data from the XIPERE® (triamcinolone acetonide injectable suspension) pivotal Phase 3 program will be presented at the American Society of Retina Specialists (ASRS) 40th annual scientific meeting, which will take place in New York from July 13-16, 2022. The presentations will include a new post-hoc analysis of the pivotal Phase 3 trial (PEACHTREE) evaluating outcomes following treatment with XIPERE® in patients with macular edema associated with chronic uveitis.

Key Points: 
  • "At this year's ASRS annual meeting, we look forward to sharing these data with retina specialists on XIPERE, which we launched commercially in March," said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb.
  • Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with uveitis: Outcomes by anatomic subtypes in PEACHTREE.
  • Efficacy of suprachoroidal triamcinolone acetonide injectable suspension in the treatment of macular edema in patients with chronic uveitis.
  • XIPERE(triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

CELEBRATE NATIONAL SUNGLASSES DAY WITH THE VISION COUNCIL ON JUNE 27

Retrieved on: 
Thursday, June 23, 2022
The Vision Council, UVA, Time, Education, Industry, Eye, Water, Pterygium, Cornea, Weather, OD, Perception, Association, Photokeratitis, Cataract, Parent, Cancer, Lens, Research, Baby boomers, Richard Genzer, Growth, Sand, Conjunctiva, UV, Snow, Radiation, Social media, UVB, Instagram, Awareness, Risk, Personal protective equipment, Renting, Toy, Millennials, Facebook

ALEXANDRIA, Va., June 23, 2022 /PRNewswire/ -- Monday, June 27 is National Sunglasses Day, the annual holiday brought to life by The Vision Council that celebrates the importance of wearing ultraviolet (UV)-protective sunwear and eyewear.

Key Points: 
  • ALEXANDRIA, Va., June 23, 2022 /PRNewswire/ -- Monday, June 27 is National Sunglasses Day, the annual holiday brought to life by The Vision Council that celebrates the importance of wearing ultraviolet (UV)-protective sunwear and eyewear.
  • As the leading trade association for the vision care industry, The Vision Council encourages everyone to always wear sunglasses when outdoors to protect their eyes from the sun's UV rays.
  • "Sunglasses are as much a health necessity as they are a fashion accessory," said Dr. Justin Bazan, OD, medical advisor to The Vision Council.
  • As the vision care leader in enabling better vision for better lives, The Vision Council positions its members for success by promoting growth in the vision care industry through education, advocacy, research, consumer outreach, strategic relationship building and industry forums.

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

Retrieved on: 
Monday, May 23, 2022
Medicine, Food, Mycosis, U.S. Securities and Exchange Commission, NCE, Infection, KALA, Visual acuity, MPP, Duane syndrome, IOP, Loteprednol, Private Securities Litigation Reform Act, Steroid, Ophthalmology, Wilmer Cutler Pickering Hale and Dorr, Tissue, Pain, Degenerative disease, Incidence, COVID-19, Marketing, Food and Drug Administration, Chickenpox, Cover My Eyes (Pain and Heaven), GLOBE, Inflammation, Company, Coronavirus, Eye, Herpes simplex, FDA, Conjunctiva, Feed additive, Sclera, Adverse drug reaction, Cornea, Security (finance), Risk, History, Vaccinia, Patient, NASDAQ, LE, Technology, Slit lamp, Glaucoma, Sale, Hart–Scott–Rodino Antitrust Improvements Act, Optic nerve, Health insurance, Pharmaceutical industry, Vaccine, Alcon

ARLINGTON, Mass., May 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has entered into a definitive agreement to sell its commercial portfolio and related intellectual property assets to Alcon Inc. This includes EYSUVIS, the first and only U.S. Food and Drug Administration (FDA) approved medicine for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease, and INVELTYS, a twice-a-day corticosteroid for the treatment of post-operative inflammation and pain following ocular surgery.

Key Points: 
  • Kala plans to focus on developing KPI-012, a novel cell-free secretome therapy that has the potential to address a number of rare and severe ocular diseases.
  • Under the terms of the asset purchase agreement, Kala will receive an upfront payment of $60 million and will be eligible to receive commercial-based sales milestone payments.
  • Piper Sandler acted as the exclusive financial advisor, and Wilmer Cutler Pickering Hale and Dorr LLP served as legal counsel to Kala.
  • Kala believes INVELTYS has a favorable profile for the treatment of inflammation and pain following ocular surgery, due to its twice-a-day dosing regimen.